Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.
The provision of this card to patients is required by the terms of the Marketing Authorisation. Please ensure that you carry this card with you at all times and that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with nivolumab or nivolumab in combination with ipilimumab. This card was updated in July 2020. Changes to the card include design/editorial updates, removal of the black inverted triangle symbol (and associated wording) and an updated reporting of side effects statement.